Presenter: John E. Lincoln
This webinar will examine the existing and proposed requirements for the U.S. FDA’s DHF, 21 CFR 820.30 and now ISO 13485:2016 7.3 including its derivative documents, the DMR and DHR. It will consider the European Union’s MDD TF/DD and its transition to the EU MDR requirements, and evaluate the documents’ differing purposes / goals, as well as the two different device classification schemes. Required and desirable contents will be discussed.
Also considered: Areas requiring frequent re-evaluation / update; Similarities and differences; Future trends; Typical DHF Table of Contents, Technical File or Design Dossier Table of Contents, The importance and usefulness of the “Essential Requirements”; Structure of the “Declaration of Conformity”,self-declaring or N-B reviewed; Parallel approaches to development. Finally, the differing approaches to file audits by the FDA and the Notified Body will be discussed.
Why You Should Attend:
One of our most popular webinars, now expanded to 3 hours, and continuously updated with the latest U.S. FDA and Eurpean Union requirements. As U.S. companies go global, they must meet different product design documentation. The cGMPs mandate Design Control and the Design History File (DHF).
In order to sell globally, the EU’s CE-marking documentation is a requirement the Technical FiIe or Design Dossier and now, Technical Documentation under the new EU MDR (Medical Device Regulation), which replaces the MDD (Medical Device Directive). Transitioning consideration / concerns.
The DHF / D&DP serve different purposes, support different goals, than the TF / DD / TD, but there are increasing similarities. And the DHF is adapting to some of the features of the TF/DD. And how / where do the DMR and DHR fit? Being aware of the similarities and differences in the files and their individual documents can further concurrent development and/or updates to both. Against the background of 21 CFR 820.30, ISO 13485:2016 7.3, and the transitioning from EU MDD to MDR.
Areas Covered in the Session :
Who Should Attend: